C07K 14/5434
Il-12
Official title: {il-12}
C07K14/5434 (Il-12) appears on 454 US grants and 893 published applications in this corpus.
Search patents in C07K- Granted patents
- 454
- Published applications
- 893
- Assignees
- 356
- Inventors
- 1,476
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 3 | 0 |
| 1998 | 6 | 0 |
| 1999 | 3 | 0 |
| 2000 | 0 | 0 |
| 2001 | 3 | 0 |
| 2002 | 2 | 7 |
| 2003 | 5 | 14 |
| 2004 | 3 | 12 |
| 2005 | 4 | 12 |
| 2006 | 7 | 7 |
| 2007 | 9 | 11 |
| 2008 | 7 | 7 |
| 2009 | 7 | 14 |
| 2010 | 5 | 13 |
| 2011 | 15 | 13 |
| 2012 | 8 | 16 |
| 2013 | 8 | 10 |
| 2014 | 11 | 15 |
| 2015 | 8 | 9 |
| 2016 | 6 | 14 |
| 2017 | 8 | 17 |
| 2018 | 6 | 21 |
| 2019 | 21 | 54 |
| 2020 | 43 | 99 |
| 2021 | 60 | 87 |
| 2022 | 48 | 84 |
| 2023 | 30 | 117 |
| 2024 | 45 | 102 |
| 2025 | 49 | 75 |
| 2026 | 20 | 63 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cytokine immunotherapy22 Sep 2026US 12,742,182 B2VLP Therapeutics, LLC
- Protein heterodimer and use thereof18 Aug 2026US 12,709,638 B2Ningbo Innovative Mechanism Bioscience LLC
- Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment18 Aug 2026US 12,709,737 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Multi-chain chimeric polypeptides and uses thereof28 Jul 2026US 12,692,295 B2ImmunityBio, Inc.
- Cell immunotherapy for the treatment of cancer14 Jul 2026US 12,678,486 B2Board of Regents, The University of Texas System
- Recombinant expression vector for secreting interleukin-12, and attenuated salmonella strain transformed therewith8 Oct 2026US 2026/0306555 A1The Industry & Academic Cooperation in Chungnam National University (IAC)
- Fusion proteins of il-24 and immunostimulatory cytokines, nk cells expressing il-24 or fusion proteins, and methods of use thereof8 Oct 2026US 2026/0308218 A1Virginia Commonwealth University
- Recombinant herpes simplex virus with il-12 expression8 Oct 2026US 2026/0308219 A1
- Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same1 Oct 2026US 2026/0295010 A1
- Cell immunotherapy for the treatment of cancer1 Oct 2026US 2026/0295011 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Human antibodies that bind human IL-12 and methods for producing300US 6,914,128 B1Abbott GmbH & Co. KG · 2005
- Derivatives of growth hormone and related proteins160US 6,608,183 B1Bolder Biotechnology, Inc. · 2003
- Multiple cytokine protein complexes145US 6,617,135 B1EMD Lexigen Research Center Corp. · 2003
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Interleukin-12 fusion protein125US 5,994,104 ARoyal Free Hospital School of Medicine · 1999